| Hazard Information | Back Directory | [Description]
Piracetam-d6 is intended for use as an internal standard for the quantification of piracetam by GC- or LC-MS. Piracetam is a nootropic cyclic GABA derivative.1 It is a positive allosteric modulator of AMPA receptors and enhances binding of the NMDA antagonist MK-801 to rat forebrain membranes.2,3 Piracetam (1 mM) protects against amyloid-β-induced decreases in the mitochondrial membrane potential, as well as decreases in neurite outgrowth in the presence of NGF, in PC12 rat adrenal medulla cells.4 It prevents scopolamine-induced amnesia in a passive avoidance test in mice when administered at a dose of 30 mg/kg.5 Formulations containing piracetam have been used in the treatment of myoclonus.WARNING This product is not for human or veterinary use. | [References]
[1] KATARZYNA WINNICKA Anna B Marian Tomasiak. Piracetam–an old drug with novel properties?[J]. Acta poloniae pharmaceutica, 2005, 62 5: 405-409.
[2] A. COPANI. Nootropic Drugs Positively Modulate α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid-Sensitive Glutamate Receptors in Neuronal Cultures[J]. Journal of Neurochemistry, 1992, 58 4: 1199-1204. DOI: 10.1111/j.1471-4159.1992.tb11329.x
[3] SERVANE M. HAMELIN John C L. Effects of putative cognition enhancers on the NMDA receptor by [3H]MK801 binding[J]. European journal of pharmacology, 1995, 281 3: Pages R11-R13. DOI: 10.1016/0014-2999(95)00432-k
[4] C KURZ. The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by beta-amyloid peptide.[J]. British Journal of Pharmacology, 2010, 160 2: 246-257. DOI: 10.1111/j.1476-5381.2010.00656.x
[5] CARLA GHELARDINI. The novel nootropic compound DM232 (UNIFIRAM) ameliorates memory impairment in mice and rats[J]. Drug Development Research, 2002, 56 1: 23-32. DOI: 10.1002/ddr.10055 |
|
|